ScinoPharm provides new epilepsy drug in the US
By Kathryn Chiu,The China PostTAIPEI, Taiwan -- ScinoPharm Taiwan (台灣神隆) on Monday announced its new active pharmaceutical ingredient (API) for treating epilepsy has been ratified and launched by Supernus Pharmaceuticals in the U.S. market last week.
September 10, 2013, 12:04 am TWN
ScinoPharm Taiwan yesterday stated that its Tainan facility facilitates the commercial manufacture of topiramate, the active pharmaceutical ingredient (API) for Trokendi XR, a new once-daily extended release formulation of topiramate for the treatment of epilepsy that was developed and recently launched by Supernus Pharmaceuticals in the U.S. market.
Supernus received approval to market Trokendi XR from the United States Food and Drug Administration in August 2013, according to an official statement from Supernus.
Epilepsy is a chronic central nervous disease wherein the sudden abnormal release of electrical impulses by neurons causes a temporary disorder in brain function.
Unlike other epilepsy drugs that require multiple doses, Trokendi XR is a novel once-daily extended-release formulation designed to improve compliance and reduce blood level fluctuations and associated side effects and breakthrough seizures, ScinoPharm said.
ScinoPharm cited the data from the U.S. Center for Disease Control and Prevention to indicate that there are approximately 2 million epilepsy sufferers in the US. The new drug is expected to attract market attention after being offered to the public.
ScinoPharm offers a wide range of product lines. Other than capturing the API market in oncological drugs, their central nervous system product portfolio has also made progress, the company said.
With CGMP-compliant facilities, ScinoPharm said it has worked on over 70 new chemical entity projects with 5 new drugs, including Trokendi XR, already approved by the U.S. FDA and 5 more entering Phase III of clinical trials.
ScinoPharm Taiwan is a major process R&D and API manufacturing service provider to the global pharmaceutical industry.
The positive report didn't give a boost to ScinoPharm's shares yesterday. ScinoPharm plummeted 3.49 percent to NT$85.9 in Taipei trading.
ScinoPharm stock has risen more than 15 percent so far this year and represented a return of over 85 percent for its investors compared with its initial public offering price of NT$46 per share.
Citigroup estimates the company's full-year revenue will rise 18.82 percent to NT$5.43 billion this year and increase by another 9 percent to NT$5.92 billion next year. It forecast net profit for this year to reach NT$1.51 billion, or NT$2.32 per share, and hit NT$1.58 billion, or NT$2.43 a share, next year, compared with last year's NT$1.17 billion, or NT$1.8 a share.